Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-4 receptor type II (IL-4R type II) is a heterodimeric cell surface receptor composed of IL-4Rα and IL-13Rα1 subunits. It mediates the biological effects of IL-4 and IL-13, playing a central role in type 2 immune responses, including host defense against parasites, allergic inflammation, asthma, and tissue fibrosis. It is predominantly expressed on nonhematopoietic cells and myeloid cells. Upon ligand binding, it activates intracellular pathways such as STAT6, driving Th2-type immune responses. Therapeutics targeting this pathway aim to modulate excessive Th2-driven inflammation.
Modulation of Th2-driven inflammation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-4 Receptor Type II.